Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...

Bristol Myers Squibb has announced that the FDA has given approval to label updates for Breyanzi and Abecma to treat multiple ...

The Polish government’s new draft law on drug reimbursement aims to streamline procedures, empower patients, and ensure ...

A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Investing.com -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock gained 2.2% premarket after the company announced that its experimental treatment for Angelman syndrome received Breakthrough ...

Updated results from the Phase II RedirecTT-1 trial show that the dual bispecific antibody regimen of Talvey and Tecvayli ...

Ultragenyx Pharmaceutical received breakthrough therapy designation from the U.S. Food and Drug Administration for its drug GTX-102, which is designed to treat people with Angelman syndrome. Angelman ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Cancer remains one of the leading causes of mortality worldwide, driving an ongoing search for more effective and selective ...